ArticleGels (Basel, Switzerland)2025
Graphene Oxide Incorporated Nanohybrid Aerogels as New Generation Drug Carrier Platforms.
Article in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biological Activities and LC-QTOF-MS-Based Phytochemical Characterization ofPharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
By combining the superior capacity of graphene oxide with alginate matrix in a nanohybrid aerogel structure, great potential can be developed for technical features and use in areas such as biomedicine. The aim of this study is the production of graphene oxide incorporated nanohybrid aerogels using ambient pressure drying technique for drug loading and release. The produced nanostructures were identified with electron microscopy, X-ray diffraction, dynamic light scattering, and spectroscopic techniques. The surface area of the nanomaterials was examined by methylene blue method. Drug adsorption capacity of the nanohybrid aerogels was investigated by conducting batch adsorption studies using the model drug diclofenac sodium (DS). The equilibrium time of drug adsorption was determined and adsorption kinetics were modeled. The adsorption equilibrium time of the drug on the adsorbent was found to be 3 h. Equilibrium data were modeled by using the Langmuir and the Freundlich isotherms and according to the Langmuir isotherm, the maximum adsorption capacity was found to be 20.83 mg/g. Results showed the potential of the produced nanohybrid aerogels to be used as drug adsorbents for drug delivery applications. The results obtained from this study will be useful in drug production and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.